Sun Pharmaceutical Industries Ltd. has reported strong growth across its business as it delivered its results for the second quarter of the 2023 financial year, although sales through its US unit fell by 9% sequentially due to a decline in sales of its generic rival to Revlimid (lenalidomide). Q2 revenue was primarily driven by Sun’s branded product portfolio.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?